Loading...
Market
Primary Focus of New Huntington's Therapeutic Strategies by End of 2025?
2
Resolution / Starting Odds
CAG Repeat Reduction • 25%
Neuroprotective Agents • 25%
Gene Editing • 25%
Other • 25%
Details from scientific publications and company announcements
Story
New Research Reveals Genetic Insights into Huntington's Disease, a Fatal Brain Disorder, and Potential for Improved Treatments
Jan 16, 2025, 05:32 PM
Recent research has provided new insights into Huntington's disease, a hereditary disorder characterized by the degeneration of nerve cells in the brain. A study revealed that an inherited genetic mutation may drive the disease, reshaping the understanding of its biological mechanisms. This research highlights the potential for new therapeutic strategies aimed at slowing or stopping the progression of the disease. Notably, findings indicate that the genetic basis of Huntington's disease involves a 'ticking DNA clock,' where CAG repeats in the DNA slowly expand throughout a person's life. These developments may lead to improved treatment options for individuals affected by this fatal condition, which often strikes in the prime of life.
View original story
Similar markets
Biomarker development • 25%
Gene therapy • 25%
Other • 25%
Neuroprotective treatments • 25%
Cancer • 25%
Other • 25%
Infectious diseases • 25%
Neurological disorders • 25%
30% to 50% • 25%
10% to 30% • 25%
Less than 10% • 25%
More than 50% • 25%
No further development • 25%
Phase 1 Clinical Trials • 25%
Partnership with NGO • 25%
Licensing Agreement • 25%
Find new partner • 25%
Discontinue • 25%
Seek acquisition • 25%
Self-commercialize • 25%
Conditional approval • 25%
BLA submission • 25%
Phase III trial initiation • 25%
No progress • 25%
No significant milestone • 25%
Phase 1 completion • 25%
Phase 2 completion • 25%
Phase 3 completion • 25%
Monoclonal Antibody • 25%
Small Molecule Drug • 25%
Gene Therapy • 25%
Other • 25%